Assessing p-tolyloxy-1,3,4-oxadiazole acetamides as lipoxygenase inhibitors assisted by in vitro and in silico studies
作者:Bushra Bashir、Naheed Riaz、Syeda Abida Ejaz、Muhammad Saleem、Muhammad Ashraf、Ambar Iqbal、Saima Muzaffar、Samina Ejaz、Aziz-ur-Rehman、Hafiz Mohammad Kashif Mahmood、Keshab Bhattarai
DOI:10.1016/j.bioorg.2022.106144
日期:2022.12
ongoing research on 1,3,4-oxadiazole derivatives deals with the synthesis of a new series of N-alkyl/aralky/aryl derivatives of 5-((p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-ylthio)acetamide (6a-o) which were developed by the sequential conversion of p-tolyloxyacetic acid (a) into ester (1) hydrazide (2) and 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol (3). The designed compounds (6a-o) were acquired by
炎症、先天免疫和癌症之间的潜在相关性广为人知,并通过三种酶介导的过程联系起来;环氧合酶 (COX)、脂肪氧化酶 (LOX) 和细胞色素 P450 (CYP 450 )。抗炎药针对靶向酶的副作用和随后产生的耐药性的报告不断增加,迫使研究人员合成具有更安全特性的新的有效分子。基于这些事实,我们正在进行的 1,3,4-恶二唑衍生物研究涉及合成一系列新的 5-(( p -tolyloxymethyl)-4H-1的N-烷基/芳烷基/芳基衍生物, 3,4-恶二唑-2-基硫基)乙酰胺 ( 6a-o )对甲苯氧基乙酸( a )转化为酯( 1 )酰肼( 2 )和5-(对甲苯氧基甲基)-4H-1,3,4-恶二唑-2-硫醇( 3 )。设计的化合物 ( 6a-o ) 是通过 1,3,4-恶二唑 ( 3 ) 与大量亲电子试剂 ( 5a-o ) 在 KOH 中反应得到的。合成的类似物 ( 6a-o ) 通过 FTIR、1